Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN3A | Q9NY46 | 4/20 | 0.42 |
| ▸ | SCN4A | P35499 | 2/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | PRKDC | P78527 | 1/20 | 0.40 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.40 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 1/20 | 0.39 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.38 |
| ▸ | TTK | P33981 | 1/20 | 0.38 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | BECN1 | Q14457 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21451631 | 0.92 | NAMPT (0.47) | SCN3ASCN4ANAMPTSCN9APRKDC | |
| SCHEMBL2028022 | 0.90 | PRKDC (0.43) | SCN3ASCN4ANAMPTSCN9APRKDC | |
| SCHEMBL20527262 | 0.87 | P2RY12 (0.43) | PRKDCP2RY12 | |
| SCHEMBL20086569 | 0.86 | NAMPT (0.47) | NAMPTPRKDCP2RY12CYP17A1DRD2 | |
| SCHEMBL21451881 | 0.85 | CYP17A1 (0.44) | NAMPTPRKDCP2RY12CYP17A1P2RY14 | |
| SCHEMBL2028684 | 0.81 | CYP17A1 (0.47) | SCN3ANAMPTSCN9APRKDCCYP17A1 | |
| SCHEMBL16710976 | 0.79 | HDAC1 (0.39) | NAMPTPRKDCP2RY12CYP17A1TTK | |
| SCHEMBL14441974 | 0.79 | ERBB2 (0.43) | NAMPTP2RY12ACSS2 | |
| SCHEMBL3417386 | 0.79 | ERBB2 (0.43) | NAMPTP2RY12ACSS2 | |
| SCHEMBL19739304 | 0.79 | CYP17A1 (0.44) | NAMPTPRKDCP2RY12CYP17A1P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20250011317-A1 | ANTI-PROLIFERATIVE AGENTS | PHEON THERAPEUTICS LTD (GB) | 2025-01-09 | — | — | US | disclosed |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2024-02-27 | — | — | US | disclosed |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2024-02-27 | — | — | US | disclosed |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2024-02-27 | — | — | US | disclosed |
| US-20230302142-A1 | Cytotoxic Agents | Pheon Therapeutics Ltd. (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230302142-A1 | Cytotoxic Agents | Pheon Therapeutics Ltd. (GB) | 2023-09-28 | — | — | US | disclosed |
| US-20230302142-A1 | Cytotoxic Agents | Pheon Therapeutics Ltd. (GB) | 2023-09-28 | — | — | US | disclosed |
| EP-4188927-A1 | CYTOTOXIC AGENTS | Pheon Therapeutics Ltd (GB) | 2023-06-07 | — | — | EP | disclosed |
| WO-2022023735-A1 | CYTOTOXIC AGENTS | FEMTOGENIX LIMITED (GB) | 2022-02-03 | — | — | WO | disclosed |
| US-20210206763-A1 | Anti-Proliferative Agents | PHEON THERAPEUTICS LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| US-10975072-B2 | Substituted 6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepines as anti-proliferative agents | FEMTOGENIX LIMITED | 2021-04-13 | — | — | US | disclosed |
| US-10975074-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | FEMTOGENIX LIMITED | 2021-04-13 | — | — | US | disclosed |
| US-20190308970-A1 | ANTI-LIFERATIVE AGENTS COMPRISING SUBSTITUTED PYRROLO-, INDOLINO- OR TETRAHYDROISOQUINOLINE-BENZODIAZEPINES | PHEON THERAPEUTICS LTD (GB) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206763-A1 | Anti-Proliferative Agents | CCND2, BRD2, DRD2 | SCN3A 2802/4885SCN4A 2120/4885NAMPT 3086/4885 |
| US-10975074-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | CNR1, GABRA1, BAK1 | SCN3A 1341/4885SCN4A 1196/4885NAMPT 1711/4885 |
| US-12583857-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | CNR1, MTNR1B, MTNR1A | SCN3A 676/4885SCN4A 840/4885NAMPT 3466/4885 |
| US-20250011317-A1 | ANTI-PROLIFERATIVE AGENTS | CCND2, BRD2, CCND3 | SCN3A 2976/4885SCN4A 2661/4885NAMPT 3065/4885 |
| US-10975072-B2 | Substituted 6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepines as anti-proliferative agents | PDCD1, CCND1, PDCD6 | SCN3A 3122/4885SCN4A 2676/4885NAMPT 3492/4885 |
| US-20190308970-A1 | ANTI-LIFERATIVE AGENTS COMPRISING SUBSTITUTED PYRROLO-, INDOLINO- OR TETRAHYDROISOQUINOLINE-BENZODIAZEPINES | GABRA1, GABBR1, GABRA2 | SCN3A 879/4885SCN4A 1329/4885NAMPT 2009/4885 |
| US-20230302142-A1 | Cytotoxic Agents | ANXA11, ANXA5, HAX1 | SCN3A 2885/4885SCN4A 1758/4885NAMPT 4507/4885 |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | MKI67, CCND2, CCND1 | SCN3A 3582/4885SCN4A 1748/4885NAMPT 2252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.